Evren U Azeloglu, PhD
- ASSOCIATE PROFESSOR | Medicine, Nephrology
- ASSOCIATE PROFESSOR | Pharmacological Sciences
Research Topics:Biomechanics/Bioengineering, Biophysics, Cardiovascular, Computational Biology, Cytoskeleton, Kidney, Mathematical Modeling of Biomedical Systems, Mathematical and Computational Biology, Nanotechnology, Signal Transduction, Systems Biology, Tissue Engineering
Dr. Azeloglu is an Associate Professor of Medicine in the Division of Nephrology with a secondary appointment in the Department of Pharmacological Sciences. He received his B.E. in Mechanical Engineering and M.S. in Biomedical Engineering from State University of New York at Stony Brook. He completed his Ph.D. in Biomedical Engineering from Columbia University in the City of New York and a postdoctoral fellowship in Department of Pharmacology and Systems Therapeutics in Icahn School of Medicine at Mount Sinai. He was awarded the Yuen-huo Hung & Chao-chin Huang Award from Columbia University and a Howard Hughes Medical Institute fellowship from the Life Science Research Foundation and a Career Development Grant from the American Society of Nephrology. His research focuses on cell and tissue biomechanics, mechanobiological signaling, systems pharmacology and tissue engineering.
Multi-Disciplinary Training AreaPharmacology and Therapeutics Discovery [PTD]
BE, Stony Brook University
MS, Stony Brook University
PhD, Columbia University
NephCure Kidney International ASN Foundation Kidney Research Award
Howard Hughes Medical Institute Fellowship
Yuen-huo Hung & Chao-chin Huang Award (2009)
Stony Wold Herbert Fellowship
Our main goal at the Systems Bioengineering Lab is to understand mechanobiological decision-making capabilities and to develop novel therapeutics for precision medicine. We employ multiscale experimental and computational techniques as well as microfabrication and tissue engineering methods to study cell signaling, biomechanics, tissue function and regeneration using human induced pluripotent stem cell-derived cardiovascular and renal model systems. We also use multi-platform omics technologies and network analyses for identification of key information processing hubs and regulatory motifs that can be used as therapeutic targets in drug development for complex diseases such as hypertension, diabetic nephropathy and heart failure. See Azeloglu Lab website for more details.